David Calkins

Researchers at Vanderbilt University Medical Center have shown for the first time that when one optic nerve in the eye is damaged, as in glaucoma, the opposite optic nerve comes to the rescue by sharing its metabolic energy. Read More

Tonia Rex and David Calkins were recently awarded National Eye Institute grants totaling $6.8 million over five years to develop new treatments for optic neuropathies and glaucoma, the leading cause of irreversible blindness. Read More

David Calkins, PhD, vice chair and director of Research at the Vanderbilt Eye Institute, has been granted one of the preeminent awards in vision research — the Research to Prevent Blindness (RPB) Stein Innovation Award. Read More

A team of researchers, led by David Calkins, PhD, vice chair and director of Research at the Vanderbilt Eye Institute, has made a breakthrough discovery in the field of glaucoma showing new hopes for treatments to preserve vision. Read More

The Vanderbilt Eye Institute (VEI) recently hosted the Southeastern Vision Conference to celebrate and share excellence in vision science. Read More

While agreeing that viewing a total solar eclipse is a chance of a lifetime, Vanderbilt Eye Institute Research Director David Calkins urges us to not look at the sun without special eclipse glasses. Catkins explains how certain spectrums of sunlight can damage your eyesight without you knowing it, until it… Read More

Researchers at Vanderbilt University Medical Center and Vanderbilt University have received a $1.9 million grant from the National Institutes of Health (NIH) to support research to restore vision through regeneration of the retina. Read More

The Vanderbilt Eye Institute recently received a grant for $115,000 from Research to Prevent Blindness, placing the total award amount for unrestricted grants from the organization at $860,000. Read More

Understanding how the protein TRPV1 helps neurons survive after glaucoma-related stressors could lead to new therapeutic strategies for glaucoma and other neurodegenerative conditions. Read More

Vanderbilt University has launched a regenerative visual neuroscience initiative to develop new ways of treating — and restoring sight to — people who have been blinded by glaucoma, macular degeneration, diabetic retinopathy and eye injuries. Read More

An ion channel protein called TRIPV1 helps retinal neurons survive the elevated eye pressure associated with glaucoma. Read More

Three years ago, a team of researchers led by David Calkins, Ph.D., vice chair and director of Research at the Vanderbilt Eye Institute, showed that the first sign of injury in glaucoma, the leading cause of blindness in the United States, occurs in the brain. Read More

David Calkins, Ph.D., vice chair and director of Research for the Vanderbilt Eye Institute, was recently awarded a Research to Prevent Blindness (RPB) Senior Scientific Investigator Award. Read More

Vision experts from around the country recently gathered at the 2012 Vanderbilt Eye Institute symposium “Regenerative Medicine in Glaucoma” to discuss the impact that regenerative medicine has on neurobiological diseases. Read More

Research to Prevent Blindness has awarded a grant of $100,000 to Vanderbilt’s Department of Ophthalmology and Visual Sciences to support research into the causes, treatment and prevention of blinding diseases. Read More